NAMS (NewAmsterdam Pharma Co NV) Beneish M-Score: -4.37 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
45 GF Score
Price $27.96
GF Value $10.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV Beneish M-Score?

NewAmsterdam Pharma Co NV NAMS +1.05% 45 Beneish M-Score is -4.37 as of Aug. 08, 2026. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 822 Biotechnology companies, NewAmsterdam Pharma Co NV ranks worse than 98.54% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Beneish M-Score or its related term are showing as below:

NAMS' s Beneish M-Score Range Over the Past 10 Years
Min: -4.37   Med: 19.78   Max: 76.13
Current: -4.37

During the past 6 years, the highest Beneish M-Score of NewAmsterdam Pharma Co NV was 76.13. The lowest was -4.37. And the median was 19.78.


NewAmsterdam Pharma Co NV Beneish M-Score Historical Data

* Premium members only.

The historical data trend for NewAmsterdam Pharma Co NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV Beneish M-Score Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 2.09 76.13

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.46 19.78 76.13 71.37 -4.37

NAMS vs ARQT, IDYA, ALMS: Beneish M-Score Comparison

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Beneish M-Score falls into.


NAMS
45GF Score
NewAmsterdam Pharma Co NV NAMS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewAmsterdam Pharma Co NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NewAmsterdam Pharma Co NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.4325+0.528 * 1+0.404 * 1.1599+0.892 * 0.1113+0.115 * 0.6678
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 9.7871+4.679 * -0.10831-0.327 * 2.3079
=-4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was $5.35 Mil.
Revenue was 3.701 + 3.04 + 0.032 + 0.348 = $7.12 Mil.
Gross Profit was 3.701 + 3.04 + 0.032 + 0.348 = $7.12 Mil.
Total Current Assets was $659.21 Mil.
Total Assets was $704.45 Mil.
Property, Plant and Equipment(Net PPE) was $0.49 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.24 Mil.
Selling, General, & Admin. Expense(SGA) was $102.28 Mil.
Total Current Liabilities was $72.97 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Net Income was -64.135 + -48.441 + -74.923 + -72.005 = $-259.50 Mil.
Non Operating Income was -5.081 + 4.329 + -15.416 + -23.575 = $-39.74 Mil.
Cash Flow from Operations was -39.214 + -30.604 + -40.875 + -32.769 = $-143.46 Mil.
Total Receivables was $19.75 Mil.
Revenue was 19.145 + 2.978 + 12.772 + 29.111 = $64.01 Mil.
Gross Profit was 19.145 + 2.978 + 12.772 + 29.111 = $64.01 Mil.
Total Current Assets was $769.85 Mil.
Total Assets was $815.11 Mil.
Property, Plant and Equipment(Net PPE) was $0.62 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.18 Mil.
Selling, General, & Admin. Expense(SGA) was $93.93 Mil.
Total Current Liabilities was $36.51 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.345 / 7.121) / (19.75 / 64.006)
=0.750597 / 0.308565
=2.4325

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(64.006 / 64.006) / (7.121 / 7.121)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (659.207 + 0.493) / 704.452) / (1 - (769.85 + 0.62) / 815.112)
=0.063527 / 0.054768
=1.1599

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.121 / 64.006
=0.1113

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.176 / (0.176 + 0.62)) / (0.244 / (0.244 + 0.493))
=0.221106 / 0.331072
=0.6678

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(102.281 / 7.121) / (93.934 / 64.006)
=14.363292 / 1.467581
=9.7871

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.056 + 72.974) / 704.452) / ((0.103 + 36.512) / 815.112)
=0.103669 / 0.04492
=2.3079

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-259.504 - -39.743 - -143.462) / 704.452
=-0.10831

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NewAmsterdam Pharma Co NV has a M-score of -4.37 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.37 mean?
NewAmsterdam Pharma Co NV (NAMS) has a Beneish M-Score of -4.37 as of Aug. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #810 out of 822 companies in the Biotechnology industry, placing it in the top 98.5%.
Is NewAmsterdam Pharma Co NV's Beneish M-Score too high?
NewAmsterdam Pharma Co NV's current Beneish M-Score is -4.37. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #810 out of 822 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Beneish M-Score compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #810 out of 822 companies for Beneish M-Score. This places NewAmsterdam Pharma Co NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current Beneish M-Score is -4.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Beneish M-Score is -4.37. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Beneish M-Score is -4.37 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • Beneish M-Score: -4.37
  • GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score

Get the complete analysis for NAMS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.96
Price
$10.42
GF Value